{"id":62659,"date":"2026-02-18T01:07:53","date_gmt":"2026-02-18T00:07:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/"},"modified":"2026-02-18T01:07:53","modified_gmt":"2026-02-18T00:07:53","slug":"flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/","title":{"rendered":"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine"},"content":{"rendered":"<div>\n<p>\n<i>Study in Science Advances shows proprietary Spherical Nucleic Acid (SNA) vaccine platform slows tumor growth and extends survival in preclinical models of HPV-related cancer<\/i><\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/5\/Flashpoint_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/22\/Flashpoint_Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/5\/Flashpoint_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/21\/Flashpoint_Logo.jpg\"><\/a><\/p>\n<p>EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of its Spherical Nucleic Acid (SNA) platform in immuno-oncology. The study, led by Flashpoint\u2019s scientific co-founder Professor Chad A. Mirkin at the International Institute for Nanotechnology at Northwestern University, describes a novel therapeutic vaccine that generates a potent and targeted immune response against established human papillomavirus (HPV)-driven cancers in a preclinical animal model.<\/p>\n<p>\nThe research, published in the journal <i>Science Advances<\/i>, details a structurally novel vaccine design where an HPV antigen and a powerful immune-stimulating adjuvant are co-engineered onto a single SNA scaffold. This architecture is the key to the vaccine\u2019s success, ensuring both components are delivered to the same immune cells in the lymph nodes, resulting in a highly coordinated and robust anti-tumor response. In humanized mouse models of HPV-positive cancer, the therapeutic vaccine significantly slowed tumor growth and extended survival.<\/p>\n<p>\nKey findings from the study highlight the unique advantages of Flashpoint\u2019s structural nanomedicine approach:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Potent Immune Activation:<\/b> The SNA vaccine elicited a strong T-cell response specifically directed at cancer cells expressing the HPV E7 antigen.<\/li>\n<li>\n<b>Superior Efficacy Through Co-delivery:<\/b> The SNA structure, which guarantees co-delivery of the antigen and adjuvant, was critical for generating a powerful therapeutic effect.<\/li>\n<li>\n<b>Therapeutic, Not Just Prophylactic:<\/b> Unlike existing HPV vaccines to prevent infection, this SNA-based approach is designed to treat active, established cancers caused by the virus.<\/li>\n<\/ul>\n<p>\nA key insight from the publication is the mechanism behind the SNA vaccine&#8217;s enhanced potency. The research demonstrates that the specific placement and orientation of the antigen within the SNA is critical for its therapeutic effect. Unlike simple mixtures where the tumor antigen and the adjuvant can be taken up by different cells, the SNA platform ensures that both components are delivered as a single unit to the same antigen-presenting cells. This simultaneous co-delivery within the lymph nodes generates a more powerful and coordinated T-cell response, effectively training the immune system to seek out and destroy cancer cells.<\/p>\n<p>\n\u201cThis publication highlights the fundamental advantage of structural nanomedicine,\u201d said Venkat Krishnamurthy, Ph.D., Chief Scientific Officer of Flashpoint Therapeutics. \u201cBy precisely engineering how therapeutic components are arranged and presented at the nanoscale, we can generate biological responses that exceed what is achieved when the same components are delivered conventionally. In this study, that architectural control translated into coordinated immune activation, tumor growth suppression, and improved survival. It is an important validation of our SNA platform and supports our strategy to advance therapeutic cancer vaccines and other immuno-oncology applications.\u201d<\/p>\n<p>\nBarry Labinger, Chief Executive Officer of Flashpoint Therapeutics, added, \u201cThese results strengthen our conviction that structural design is a powerful lever in medicine. We are focused on translating this platform into clinically meaningful therapies and building a pipeline that leverages this differentiated approach.\u201d<\/p>\n<p>\nHPV is the leading cause of cervical, anal, and head and neck cancers. While prophylactic vaccines against HPV are effective, there remains a significant unmet need for better treatments for patients who are unvaccinated and develop advanced HPV-related malignancies.<\/p>\n<p>\n<b>About Flashpoint Therapeutics<\/b><\/p>\n<p>\nFlashpoint Therapeutics is a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines. Our platform enables the creation of targeted therapies that co-deliver optimized combinations of therapeutic components directly to individual cells, enhancing drug delivery, stability, potency, and safety. This modular approach supports a broad range of therapies, encompassing modalities like mRNA, siRNA, DNA, proteins, and CRISPR. The company\u2019s proprietary discovery platform is founded on nanotechnology research developed over the past decade at the laboratory of Prof. Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University. Through strategic licensing and acquisition transactions with Northwestern University, Holden Pharmaceuticals, and Exicure, Flashpoint has assembled more than 150 issued patents and patent applications covering nucleic acid, protein, and CRISPR gene editing therapeutics. The company is funded by key investors, including Beta Lab and CS Venture Opportunities Fund. The company has also established an important partnership with King Abdullah International Medical Research Center (KAIMRC), which will advance the technology platform via the Flashpoint-KAIMRC Center of Excellence in Structural Nanomedicine and clinical trials in Saudi research institutions.<\/p>\n<p>\nFor more information about Flashpoint Therapeutics, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.flashpoint.bio&amp;esheet=54427672&amp;newsitemid=20260217673901&amp;lan=en-US&amp;anchor=www.flashpoint.bio&amp;index=1&amp;md5=210f15176bd32547571471e2f50a45d5\" rel=\"nofollow\" shape=\"rect\">www.flashpoint.bio<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Relations:<\/b><br \/>Rosie Gonzalez<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x6d;&#x65;&#100;ia&#x40;&#x66;&#x6c;&#97;&#115;h&#x70;&#x6f;&#x69;&#110;&#116;&#46;&#x62;&#x69;&#x6f;\" rel=\"nofollow\" shape=\"rect\">&#109;&#x65;&#100;&#x69;a&#64;&#x66;&#108;&#x61;s&#x68;p&#111;&#x69;&#110;&#x74;&#46;&#x62;&#x69;&#111;<\/a><br \/>847-922-9385<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Study in Science Advances shows proprietary Spherical Nucleic Acid (SNA) vaccine platform slows tumor growth and extends survival in preclinical models of HPV-related cancer EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of its Spherical Nucleic Acid (SNA) platform in &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62659","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Study in Science Advances shows proprietary Spherical Nucleic Acid (SNA) vaccine platform slows tumor growth and extends survival in preclinical models of HPV-related cancer EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of its Spherical Nucleic Acid (SNA) platform in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T00:07:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/22\/Flashpoint_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine\",\"datePublished\":\"2026-02-18T00:07:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/\"},\"wordCount\":750,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260217673901\\\/en\\\/2723241\\\/22\\\/Flashpoint_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/\",\"name\":\"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260217673901\\\/en\\\/2723241\\\/22\\\/Flashpoint_Logo.jpg\",\"datePublished\":\"2026-02-18T00:07:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260217673901\\\/en\\\/2723241\\\/22\\\/Flashpoint_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260217673901\\\/en\\\/2723241\\\/22\\\/Flashpoint_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine - Pharma Trend","og_description":"Study in Science Advances shows proprietary Spherical Nucleic Acid (SNA) vaccine platform slows tumor growth and extends survival in preclinical models of HPV-related cancer EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of its Spherical Nucleic Acid (SNA) platform in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-18T00:07:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/22\/Flashpoint_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine","datePublished":"2026-02-18T00:07:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/"},"wordCount":750,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/22\/Flashpoint_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/","url":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/","name":"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/22\/Flashpoint_Logo.jpg","datePublished":"2026-02-18T00:07:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/22\/Flashpoint_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260217673901\/en\/2723241\/22\/Flashpoint_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62659"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62659\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}